| pubmed-article:17889125 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17889125 | lifeskim:mentions | umls-concept:C0376387 | lld:lifeskim |
| pubmed-article:17889125 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:17889125 | lifeskim:mentions | umls-concept:C0085149 | lld:lifeskim |
| pubmed-article:17889125 | lifeskim:mentions | umls-concept:C0209368 | lld:lifeskim |
| pubmed-article:17889125 | lifeskim:mentions | umls-concept:C0663182 | lld:lifeskim |
| pubmed-article:17889125 | lifeskim:mentions | umls-concept:C0596475 | lld:lifeskim |
| pubmed-article:17889125 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:17889125 | lifeskim:mentions | umls-concept:C1515568 | lld:lifeskim |
| pubmed-article:17889125 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:17889125 | pubmed:dateCreated | 2007-9-24 | lld:pubmed |
| pubmed-article:17889125 | pubmed:abstractText | Tacrolimus (TAC) with mycophenolate mofetil (MMF) and a steroid-free regimen seems to have good efficacy in preventing acute rejection in cardiac transplant recipients, although concern exists about nephrotoxicity. Induction therapy with Daclizumab seems to give protection without side effects. Data are lacking about the outcome of 2-dose Daclizumab+TAC+MMF and a steroid-free regimen. | lld:pubmed |
| pubmed-article:17889125 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17889125 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17889125 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17889125 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17889125 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17889125 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17889125 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17889125 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17889125 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17889125 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17889125 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17889125 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17889125 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17889125 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17889125 | pubmed:issn | 0041-1345 | lld:pubmed |
| pubmed-article:17889125 | pubmed:author | pubmed-author:CorderoAA | lld:pubmed |
| pubmed-article:17889125 | pubmed:author | pubmed-author:HerrerosJJ | lld:pubmed |
| pubmed-article:17889125 | pubmed:author | pubmed-author:RabagoGG | lld:pubmed |
| pubmed-article:17889125 | pubmed:author | pubmed-author:UbillaMM | lld:pubmed |
| pubmed-article:17889125 | pubmed:author | pubmed-author:MastrobuoniSS | lld:pubmed |
| pubmed-article:17889125 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17889125 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:17889125 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17889125 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17889125 | pubmed:pagination | 2163-6 | lld:pubmed |
| pubmed-article:17889125 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:meshHeading | pubmed-meshheading:17889125... | lld:pubmed |
| pubmed-article:17889125 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17889125 | pubmed:articleTitle | Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience. | lld:pubmed |
| pubmed-article:17889125 | pubmed:affiliation | Departamento de Cirugía Cardiovascular, Clinica Universitaria de Navarra, Universidad de Navarra, Pamplona, Spain. | lld:pubmed |
| pubmed-article:17889125 | pubmed:publicationType | Journal Article | lld:pubmed |
